Vasoactive Biomarkers Associated With Long-Term Incidence of Symptomatic Peripheral Arterial Disease and Mortality

Dakhel, Ardwan; Engström, Gunnar; Melander, Olle; Acosta, Stefan; Fatemi, Shahab; Gottsäter, Anders; Zarrouk, Moncef

doi:10.1177/0003319720987739

Cited by 6 publications

(3 citation statements)

References 26 publications

(54 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A substantial subset of circulating biomarkers—C-terminal endothelin-1 (CT-proET-1), N-terminal prosomatostatin ([NT-proSST), midregional proatrial natriuretic peptide (MR-proANP), procalcitonin (PCT), and copeptin—were prospectively evaluated for their role in PAD development and mortality in 3618 men and 1542 women in the Malmö Preventive Project [ 75 ]. Increased levels of CT-proET-1, NT-proSST, and MR-proANP were independently associated with incident PAD, whereas all the vasoactive biomarkers were independently associated with mortality during the 11-year follow-up [ 75 ].…”

Section: Differences In Circulating Biomarkers Of Pad and Chdmentioning

confidence: 99%

Inflammatory and Prothrombotic Biomarkers, DNA Polymorphisms, MicroRNAs and Personalized Medicine for Patients with Peripheral Arterial Disease

Poredoš

Šabovič

Mijovski

et al. 2022

IJMS

View full text Add to dashboard Cite

Classical risk factors play a major role in the initiation and development of atherosclerosis. However, the estimation of risk for cardiovascular events based only on risk factors is often insufficient. Efforts have been made to identify biomarkers that indicate ongoing atherosclerosis. Among important circulating biomarkers associated with peripheral arterial disease (PAD) are inflammatory markers which are determined by the expression of different genes and epigenetic processes. Among these proinflammatory molecules, interleukin-6, C-reactive protein, several adhesion molecules, CD40 ligand, osteoprotegerin and others are associated with the presence and progression of PAD. Additionally, several circulating prothrombotic markers have a predictive value in PAD. Genetic polymorphisms significantly, albeit moderately, affect risk factors for PAD via altered lipoprotein metabolism, diabetes, arterial hypertension, smoking, inflammation and thrombosis. However, most of the risk variants for PAD are located in noncoding regions of the genome and their influence on gene expression remains to be explored. MicroRNAs (miRNAs) are single-stranded, noncoding RNAs that modulate gene expression at the post-transcriptional level. Patterns of miRNA expression, to some extent, vary in different atherosclerotic cardiovascular diseases. miRNAs appear to be useful in the detection of PAD and the prediction of progression and revascularization outcomes. In conclusion, taking into account one’s predisposition to PAD, i.e., DNA polymorphisms and miRNAs, together with circulating inflammatory and coagulation markers, holds promise for more accurate prediction models and personalized therapeutic options.

show abstract

Section: Differences In Circulating Biomarkers Of Pad and Chdmentioning

confidence: 99%

Inflammatory and Prothrombotic Biomarkers, DNA Polymorphisms, MicroRNAs and Personalized Medicine for Patients with Peripheral Arterial Disease

Poredoš

Šabovič

Mijovski

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

“… 10 , 11 Regarding population-based studies, CT-proET-1 was recently shown to be associated with all-cause mortality in a Swedish population. 31 …”

Section: Discussionmentioning

confidence: 99%

Association of C-Terminal Pro-Endothelin-1 with Mortality in the Population-Based KORA F4 Study

Then¹,

Sujana²,

Herder³

et al. 2022

VHRM

View full text Add to dashboard Cite

Introduction Endothelin-1 and its prohormone C-terminal pro-endothelin-1 (CT-proET-1) have been linked to metabolic alterations, inflammatory responses and cardiovascular events in selected study populations. We analyzed the association of CT-proET-1 with cardiovascular events and mortality, carotid intima-media-thickness as surrogate for early atherosclerotic lesions, biomarkers of subclinical inflammation and adipokines in a population-based study. Methods The cross-sectional and prospective analyses used data from the KORA F4 study with a median follow-up time of 9.1 (8.8–9.4) years. Data on CT-proET-1 and mortality were available for 1554 participants, data on the other outcomes in subgroups (n = 596–1554). The associations were estimated using multivariable linear regression and Cox proportional hazard models adjusted for sex, age, body mass index, estimated glomerular filtration rate, arterial hypertension, diabetes, low-density and high-density lipoprotein cholesterol, current and former smoking and physical activity. The Bonferroni method was used to correct for multiple testing. Results In the fully adjusted model, CT-proET-1 was associated with cardiovascular (hazard ratio (HR) per standard deviation increase: 1.66; 95% confidence interval (CI): 1.10–2.51; p = 0.017) and all-cause mortality (HR: 2.03; 95% CI 1.55–2.67; p < 0.001), but not with cardiovascular events, and was inversely associated with the intima-media thickness (β: −0.09 ± 0.03; p = 0.001). CT-proET-1 was positively associated with five out of ten biomarkers of subclinical inflammation and with two out of five adipokines after correction for multiple testing. After inclusion of biomarkers of subclinical inflammation in the Cox proportional hazard model, the association of CT-proET-1 with all-cause mortality persisted (p < 0.001). Conclusion These results emphasize the complexity of endothelin-1 actions and/or indicator functions of CT-proET-1. CT-proET-1 is a risk marker for all-cause mortality, which is likely independent of vascular endothelin-1 actions, cardiovascular disease and inflammation.

show abstract

“…The pathophysiology of peripheral artery disease (PAD) includes an inflammatory, atherosclerotic and hypercoagulable state involving vascular endothelial cells, vascular smooth muscle cells and inflammatory cells [44]. Biomarkers can be used to evaluate different stages of this process caused by endothelial and macrovascular dysfunction [44]. It is of potential relevance to assess the role of endocan in patients with PAD (e.g.…”

Section: Endocan and Peripheral Artery Diseasementioning

confidence: 99%

Endocan: a new marker of endothelial function

Balta

Mikhailidis

2021

Current Opinion in Cardiology

View full text Add to dashboard Cite

Purpose of reviewTo consider the role of endocan as an inflammatory marker in cardiovascular diseases. Recent findingsEndocan, an endothelial inflammatory marker, is associated with cardiovascular disease. SummaryVascular endothelial inflammation plays a key role in the pathogenesis of inflammatory and cardiovascular diseases by influencing thrombogenesis, tumour invasion and secretion of bioactive mediators. We discuss the role of endocan mainly in the context of cardiology.

show abstract

Vasoactive Biomarkers Associated With Long-Term Incidence of Symptomatic Peripheral Arterial Disease and Mortality

Cited by 6 publications

References 26 publications

Inflammatory and Prothrombotic Biomarkers, DNA Polymorphisms, MicroRNAs and Personalized Medicine for Patients with Peripheral Arterial Disease

Inflammatory and Prothrombotic Biomarkers, DNA Polymorphisms, MicroRNAs and Personalized Medicine for Patients with Peripheral Arterial Disease

Association of C-Terminal Pro-Endothelin-1 with Mortality in the Population-Based KORA F4 Study

Endocan: a new marker of endothelial function

Contact Info

Product

Resources

About